Sign in Sign up for free

Free Stock Screener

Load
Save
Create a watchlist Help
 
–
×
–
×
–
×
–
×
–
×
–
×
–
×
–
day ×
–
day ×
–
% ×
–
% ×
×
–
×
–
×
–
×
–
×
–
×
–
×
–
×
–
% ×
–
% ×
–
% ×
–
×
–
×
–
×
–
×
–
% ×
–
% ×
–
% ×
–
×
–
×
–
% ×
–
% ×
–
% ×
–
% ×
–
% ×
–
day ×
–
% ×
–
% ×
–
% ×
–
% ×
–
% ×
–
% ×
–
% ×
–
% ×
–
% ×
–
% ×
–
×
–
×
–
×
–
% ×
–
×
–
×
–
% ×
–
×
–
×
–
×
–
×
–
×

FCCY
1st Constitution Bancorp
Compare

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

XSLX
XSLX
(in millions USD) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Current assets
Cash $273.946 $215.677 $165.901 $21.995
Short term investments
Net receivables
Inventory
Total current assets
Long term investments
Property, plant & equipment $29.117 $29.75 $30.328 $30.893
Goodwill & intangible assets $35.765 $35.844 $35.922 $36.003
Total noncurrent assets
Total investments $1,517.201 $1,453.413 $1,519.891 $1,665.596
Total assets $1,910.54 $1,789.245 $1,806.231 $1,806.909
Current liabilities
Accounts payable
Deferred revenue
Short long term debt
Total current liabilities
Long term debt
Total noncurrent liabilities
Total debt $34.773 $35.169 $35.55 $45.769
Total liabilities $1,710.617 $1,593.588 $1,614.968 $1,619.252
Stockholders' equity
Retained earnings $87.735 $83.333 $79.208 $75.201
Other stockholder equity $0.821 $1.288 $1.334 $1.932
Total stockholder equity $199.923 $195.657 $191.263 $187.657
(in millions USD) 2020 2019 2018
Current assets
Cash $21.995 $14.842 $16.844
Short term investments
Net receivables
Inventory
Total current assets
Long term investments
Property, plant & equipment $30.893 $33.219 $11.653
Goodwill & intangible assets $36.003 $36.779 $12.258
Total noncurrent assets
Total investments $1,665.596 $1,445.086 $1,089.576
Total assets $1,806.909 $1,586.262 $1,177.833
Current liabilities
Accounts payable
Deferred revenue
Short long term debt
Total current liabilities
Long term debt
Total noncurrent liabilities
Total debt $45.769 $129.224 $90.332
Total liabilities $1,619.252 $1,415.684 $1,050.748
Stockholders' equity
Retained earnings $75.201 $60.791 $49.75
Other stockholder equity $1.932 $0.191 -$1.833
Total stockholder equity $187.657 $170.578 $127.085

Income statement

XSLX
XSLX
(in millions USD) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Revenue
Total revenue $18.111 $17.575 $17.956 $19.36
Cost of revenue
Gross profit $18.111 $17.575 $17.956 $19.36
Operating activities
Research & development
Selling, general & administrative $8.334 $8.125 $8.754 $9.053
Total operating expenses $10.841 $10.531 $11.101 $11.163
Operating income $7.27 $7.044 $6.855 $8.197
Income from continuing operations
EBIT $7.27 $7.044 $6.855 $8.197
Income tax expense $1.84 $1.892 $1.926 $2.132
Interest expense
Net income
Net income $5.43 $5.152 $4.929 $6.065
Income (for common shares) $5.43 $5.152 $4.929 $6.065
(in millions USD) 2020 2019 2018
Revenue
Total revenue $66.448 $54.223 $50.45
Cost of revenue
Gross profit $66.448 $54.223 $50.45
Operating activities
Research & development
Selling, general & administrative $33.328 $26.911 $24.808
Total operating expenses $41.755 $35.549 $34.085
Operating income $24.693 $18.674 $16.365
Income from continuing operations
EBIT $24.693 $18.674 $16.365
Income tax expense $6.607 $5.04 $4.317
Interest expense
Net income
Net income $18.086 $13.634 $12.048
Income (for common shares) $18.086 $13.634 $12.048

Cash flows

XSLX
XSLX
(in millions USD) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Net income $5.43 $5.152 $4.929 $6.065
Operating activities
Depreciation $0.467 $0.483 $0.476 $0.492
Business acquisitions & disposals
Stock-based compensation $0.258 $0.302 $0.271 $0.276
Total cash flows from operations $30.503 $10.108 $26.789 $19.073
Investing activities
Capital expenditures -$0.102 -$0.166 -$0.184 -$0.173
Investments -$64.316 $56.006 $129.742 $28.163
Total cash flows from investing -$63.779 $55.84 $129.558 $27.991
Financing activities
Dividends paid -$1.028 -$1.027 -$0.922 -$0.922
Sale and purchase of stock $0.073 $0.013 -$0.074 $0.034
Net borrowings -$9.825 -$96.042
Total cash flows from financing $91.545 -$16.172 -$12.441 -$45.124
Effect of exchange rate
Change in cash and equivalents $58.269 $49.776 $143.906 $1.94
(in millions USD) 2020 2019 2018
Net income $18.086 $13.634 $12.048
Operating activities
Depreciation $2.053 $1.444 $1.389
Business acquisitions & disposals $7.44 -$0.996
Stock-based compensation $1.132 $1.104 $1.019
Total cash flows from operations $6.659 $13.262 $17.328
Investing activities
Capital expenditures -$0.421 -$0.161 -$0.648
Investments -$198.637 -$117.128 -$9.348
Total cash flows from investing -$198.878 -$109.949 -$9.924
Financing activities
Dividends paid -$3.676 -$2.593 -$2.12
Sale and purchase of stock -$0.204 $0.149 $0.088
Net borrowings -$82.225 $20.275 $51.275
Total cash flows from financing $199.372 $94.685 -$9.314
Effect of exchange rate
Change in cash and equivalents $7.153 -$2.002 -$1.91

ABMD
Abiomed Inc.
Compare

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

XSLX
XSLX
(in millions USD) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Current assets
Cash $182.335 $180.492 $132.818 $144.255
Short term investments $638.037 $663.829 $625.789 $524.966
Net receivables $94.475 $91.102 $90.608 $88.952
Inventory $102.237 $95.373 $93.981 $90.199
Total current assets $1,062.798 $1,060.359 $976.473 $885.006
Long term investments $116.871 $159.876 $220.089 $262.635
Property, plant & equipment $195.157 $198.478 $202.49 $196.88
Goodwill & intangible assets $109.793 $113.023 $116.304 $117.727
Total noncurrent assets $633.746 $643.277 $696.92 $707.871
Total investments $754.908 $823.705 $845.878 $787.601
Total assets $1,696.544 $1,703.636 $1,673.393 $1,592.877
Current liabilities
Accounts payable $35.07 $34.797 $35.346 $32.066
Deferred revenue $25.962 $23.624 $26.362 $24.867
Short long term debt
Total current liabilities $134.06 $140.762 $138.457 $126.796
Long term debt
Total noncurrent liabilities $22.697 $26.678 $31.61 $33.143
Total debt
Total liabilities $156.757 $167.44 $170.067 $159.939
Stockholders' equity
Retained earnings $1,125.199 $1,019.066 $964.512 $904.187
Other stockholder equity -$46.645 -$38.271 -$27.16 -$20.489
Total stockholder equity $1,539.787 $1,536.196 $1,503.326 $1,432.938
(in millions USD) 2022 2021 2020
Current assets
Cash $132.818 $232.71 $192.341
Short term investments $625.789 $350.985 $250.775
Net receivables $90.608 $97.179 $84.65
Inventory $93.981 $81.059 $90.088
Total current assets $976.473 $787.965 $635.863
Long term investments $220.089 $264.085 $207.795
Property, plant & equipment $202.49 $197.129 $164.931
Goodwill & intangible assets $116.304 $120.718 $31.969
Total noncurrent assets $696.92 $706.394 $580.599
Total investments $845.878 $615.07 $458.57
Total assets $1,673.393 $1,494.359 $1,216.462
Current liabilities
Accounts payable $35.346 $34.842 $32.774
Deferred revenue $26.362 $24.322 $19.147
Short long term debt
Total current liabilities $138.457 $128.969 $131.885
Long term debt
Total noncurrent liabilities $31.61 $35.715 $19.111
Total debt
Total liabilities $170.067 $164.684 $150.996
Stockholders' equity
Retained earnings $964.512 $828.007 $602.482
Other stockholder equity -$27.16 -$11.445 -$11.189
Total stockholder equity $1,503.326 $1,329.675 $1,065.466

Income statement

XSLX
XSLX
(in millions USD) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Revenue
Total revenue $265.921 $277.149 $269.85 $261.176
Cost of revenue $48.88 $52.626 $51.457 $47.627
Gross profit $217.041 $224.523 $218.393 $213.549
Operating activities
Research & development $42.089 $40.477 $43.785 $40.869
Selling, general & administrative $116.958 $117.996 $109.605 $107.618
Total operating expenses $159.047 $158.473 $153.39 $148.983
Operating income $57.994 $66.05 $65.003 $64.566
Income from continuing operations
EBIT $138.703 $69.822 $74.762 $57.877
Income tax expense $32.57 $15.268 $14.437 $12.125
Interest expense
Net income
Net income $106.133 $54.554 $60.325 $45.752
Income (for common shares) $106.133 $54.554 $60.325 $45.752
(in millions USD) 2022 2021 2020
Revenue
Total revenue $1,031.753 $847.522 $840.883
Cost of revenue $188.158 $161.907 $151.305
Gross profit $843.595 $685.615 $689.578
Operating activities
Research & development $163.403 $121.875 $98.759
Selling, general & administrative $423.486 $334.183 $341.6
Total operating expenses $702.875 $456.058 $440.359
Operating income $140.72 $229.557 $249.219
Income from continuing operations
EBIT $190.56 $288.22 $256.825
Income tax expense $54.055 $62.695 $53.816
Interest expense
Net income
Net income $136.505 $225.525 $203.009
Income (for common shares) $136.505 $225.525 $203.009

Cash flows

XSLX
XSLX
(in millions USD) 30 Sep 2022 30 Jun 2022 31 Mar 2022 31 Dec 2021
Net income $106.133 $54.554 $60.325 $45.752
Operating activities
Depreciation $6.724 $6.62 $7.29 $6.926
Business acquisitions & disposals $39.995
Stock-based compensation $16.014 $13.362 $11.989 $12.383
Total cash flows from operations $13.421 $68.103 $78.972 $90.487
Investing activities
Capital expenditures -$5.609 -$6.783 -$14.891 -$6.478
Investments $67.181 $14.897 -$77.683 -$173.543
Total cash flows from investing $101.567 $8.114 -$92.574 -$180.021
Financing activities
Dividends paid
Sale and purchase of stock -$108.33 -$12.986 $4.875 $0.44
Net borrowings
Total cash flows from financing -$110.182 -$23.936 $4.745 -$6.161
Effect of exchange rate -$2.963 -$4.607 -$2.58 -$1.932
Change in cash and equivalents $1.843 $47.674 -$11.437 -$97.627
(in millions USD) 2022 2021 2020
Net income $136.505 $225.525 $203.009
Operating activities
Depreciation $28.089 $24.097 $20.43
Business acquisitions & disposals -$82.821 $15.699
Stock-based compensation $52.729 $47.006 $39.781
Total cash flows from operations $285.39 $274.578 $314.92
Investing activities
Capital expenditures -$35.763 -$53.383 -$44.006
Investments -$262.406 -$185.66 -$81.449
Total cash flows from investing -$380.99 -$223.344 -$125.455
Financing activities
Dividends paid
Sale and purchase of stock $16.658 $3.244 -$76.028
Net borrowings
Total cash flows from financing -$2.202 -$8.067 -$117.715
Effect of exchange rate -$2.09 -$2.798 -$0.43
Change in cash and equivalents -$99.892 $40.369 $71.32

XLRN
Acceleron Pharma Inc
Compare

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

XSLX
XSLX
(in millions USD) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Current assets
Cash $336.456 $336.199 $455.513 $670.952
Short term investments $254.113 $287.151 $231.736 $178.951
Net receivables $34.195 $27.937 $25.207 $26.101
Inventory
Total current assets $696.608 $717.773 $737.612 $893.269
Long term investments $61.95 $89.194 $108.193 $7.585
Property, plant & equipment $27.745 $27.379 $28.271 $29.756
Goodwill & intangible assets
Total noncurrent assets $91.24 $118.279 $138.181 $39.068
Total investments $316.063 $376.345 $339.929 $186.536
Total assets $787.848 $836.052 $875.793 $932.337
Current liabilities
Accounts payable $5.086 $9.438 $4.463 $8.472
Deferred revenue
Short long term debt $8.163 $7.552 $7.282 $7.01
Total current liabilities $57.371 $59.478 $49.819 $60.163
Long term debt $11.951 $13.167 $15.143 $17.067
Total noncurrent liabilities $12.324 $13.54 $15.143 $17.067
Total debt $20.114 $20.719 $22.425 $24.077
Total liabilities $69.695 $73.018 $64.962 $77.23
Stockholders' equity
Retained earnings -$1,074.894 -$1,004.429 -$940.908 -$877.437
Other stockholder equity -$0.398 -$0.409 -$0.417 -$0.288
Total stockholder equity $718.153 $763.034 $810.831 $855.107
(in millions USD) 2020 2019 2018
Current assets
Cash $670.952 $237.677 $145.649
Short term investments $178.951 $193.692 $147.26
Net receivables $26.101 $8.547 $7.039
Inventory
Total current assets $893.269 $449.916 $306.013
Long term investments $7.585 $22.477
Property, plant & equipment $29.756 $30.72 $7.106
Goodwill & intangible assets
Total noncurrent assets $39.068 $54.99 $8.808
Total investments $186.536 $216.169 $147.26
Total assets $932.337 $504.906 $314.821
Current liabilities
Accounts payable $8.472 $2.295 $0.419
Deferred revenue
Short long term debt $7.01 $6.183
Total current liabilities $60.163 $33.373 $18.912
Long term debt $17.067 $20.201
Total noncurrent liabilities $17.067 $22.057 $3.872
Total debt $24.077 $26.384
Total liabilities $77.23 $55.43 $22.784
Stockholders' equity
Retained earnings -$877.437 -$711.407 -$586.549
Other stockholder equity -$0.288 $0.023 -$0.56
Total stockholder equity $855.107 $449.476 $292.037

Income statement

XSLX
XSLX
(in millions USD) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Revenue
Total revenue $34.199 $27.94 $24.758 $25.867
Cost of revenue
Gross profit $34.199 $27.94 $24.758 $25.867
Operating activities
Research & development $59.717 $56.13 $57.299 $57.254
Selling, general & administrative $45.112 $35.472 $31.062 $26.207
Total operating expenses $104.829 $91.602 $88.361 $83.461
Operating income -$70.63 -$63.662 -$63.603 -$57.594
Income from continuing operations
EBIT -$70.45 -$63.513 -$63.466 -$57.405
Income tax expense $0.015 $0.008 $0.005 -$0.01
Interest expense
Net income
Net income -$70.465 -$63.521 -$63.471 -$57.395
Income (for common shares) -$70.465 -$63.521 -$63.471 -$57.395
(in millions USD) 2020 2019 2018
Revenue
Total revenue $92.523 $73.993 $13.991
Cost of revenue
Gross profit $92.523 $73.993 $13.991
Operating activities
Research & development $173.917 $153.953 $103.902
Selling, general & administrative $85.912 $56.485 $34.503
Total operating expenses $259.829 $210.438 $138.405
Operating income -$167.306 -$136.445 -$124.414
Income from continuing operations
EBIT -$166.009 -$124.92 -$118.898
Income tax expense $0.021 -$0.062 -$0.027
Interest expense
Net income
Net income -$166.03 -$124.858 -$118.871
Income (for common shares) -$166.03 -$124.858 -$118.871

Cash flows

XSLX
XSLX
(in millions USD) 30 Sep 2021 30 Jun 2021 31 Mar 2021 31 Dec 2020
Net income -$70.465 -$63.521 -$63.471 -$57.395
Operating activities
Depreciation $2.82 $2.651 $2.6 $2.524
Business acquisitions & disposals
Stock-based compensation $11.421 $13.479 $15.626 $8.432
Total cash flows from operations -$70.888 -$84.415 -$67.924 -$38.13
Investing activities
Capital expenditures -$2.409 -$0.969 -$0.92 -$0.9
Investments $59.2 -$36.165 -$150.293 -$28.7
Total cash flows from investing $56.791 -$37.134 -$151.213 -$29.6
Financing activities
Dividends paid
Sale and purchase of stock $14.153 $2.235 $3.698 $8.997
Net borrowings
Total cash flows from financing $14.153 $2.235 $3.698 $8.997
Effect of exchange rate
Change in cash and equivalents $0.056 -$119.314 -$215.439 -$58.733
(in millions USD) 2020 2019 2018
Net income -$166.03 -$124.858 -$118.871
Operating activities
Depreciation $9.614 $9.084 $3.747
Business acquisitions & disposals
Stock-based compensation $30.237 $22.995 $24.569
Total cash flows from operations -$130.327 -$93.804 -$94.706
Investing activities
Capital expenditures -$4.203 -$3.287 -$2.59
Investments $29.799 -$68.004 $125.517
Total cash flows from investing $25.596 -$71.291 $122.927
Financing activities
Dividends paid
Sale and purchase of stock $538.006 $258.72 $17.016
Net borrowings -$0.139
Total cash flows from financing $538.006 $258.72 $16.146
Effect of exchange rate
Change in cash and equivalents $433.275 $93.625 $44.367

AGFS
AgroFresh Solutions Inc
Compare

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

XSLX
XSLX
(in millions USD) 31 Dec 2022 30 Sep 2022 30 Jun 2022 31 Mar 2022
Current assets
Cash $54.355 $35.647 $51.546 $59.266
Short term investments
Net receivables $58.407 $60.491 $38.697 $55.754
Inventory $25.428 $24.757 $26.944 $22.357
Total current assets $158.73 $144.088 $140.105 $160.926
Long term investments
Property, plant & equipment $11.698 $10.968 $11.385 $11.699
Goodwill & intangible assets $504.441 $514.128 $525.186 $535.97
Total noncurrent assets $538.98 $544.843 $556.776 $567.963
Total investments
Total assets $697.71 $688.931 $696.881 $728.889
Current liabilities
Accounts payable $20.869 $12.382 $16.745 $17.124
Deferred revenue
Short long term debt $3.088 $3.139 $3.278 $3.378
Total current liabilities $66.435 $49.445 $45.224 $50.076
Long term debt $253.058 $253.24 $253.516 $253.807
Total noncurrent liabilities $288.109 $292.234 $292.148 $295.588
Total debt $256.146 $256.379 $256.794 $257.185
Total liabilities $354.544 $341.679 $337.372 $345.664
Stockholders' equity
Retained earnings -$282.017 -$273.901 -$269.763 -$251.747
Other stockholder equity -$45.643 -$52.887 -$47.589 -$44.197
Total stockholder equity $174.03 $181.977 $197.09 $223.72
(in millions USD) 2022 2021 2020
Current assets
Cash $54.355 $61.93 $50.03
Short term investments
Net receivables $58.407 $53.538 $63.204
Inventory $25.428 $19.78 $24.579
Total current assets $158.73 $155.126 $155.032
Long term investments
Property, plant & equipment $11.698 $11.986 $12.432
Goodwill & intangible assets $504.441 $546.652 $596.126
Total noncurrent assets $538.98 $577.436 $630.751
Total investments
Total assets $697.71 $732.562 $785.783
Current liabilities
Accounts payable $20.869 $16.969 $19.634
Deferred revenue
Short long term debt $3.088 $3.362 $3.378
Total current liabilities $66.435 $49.707 $52.459
Long term debt $253.058 $254.194 $264.491
Total noncurrent liabilities $288.109 $295.283 $308.757
Total debt $256.146 $257.556 $267.869
Total liabilities $354.544 $344.99 $361.216
Stockholders' equity
Retained earnings -$282.017 -$248.66 -$244.836
Other stockholder equity -$45.643 -$46.364 -$31.667
Total stockholder equity $174.03 $230.399 $272.393

Income statement

XSLX
XSLX
(in millions USD) 31 Dec 2022 30 Sep 2022 30 Jun 2022 31 Mar 2022
Revenue
Total revenue $48.532 $47.764 $25.752 $39.889
Cost of revenue $16.674 $15.552 $9.292 $11.923
Gross profit $31.858 $32.212 $16.46 $27.966
Operating activities
Research & development $2.977 $3.15 $2.884 $3.051
Selling, general & administrative $12.787 $13.537 $14.334 $11.892
Total operating expenses $26.38 $27.293 $27.926 $25.661
Operating income $5.478 $4.919 -$11.466 $2.305
Income from continuing operations
EBIT $0.461 $2.061 -$15.982 $1.696
Income tax expense $2.074 $0.535 -$3.058 -$0.164
Interest expense $6.503 $5.664 $5.092 $4.947
Net income
Net income -$8.116 -$4.138 -$18.016 -$3.087
Income (for common shares) -$14.913 -$10.801 -$24.549 -$9.523
(in millions USD) 2022 2021 2020
Revenue
Total revenue $161.937 $165.989 $157.643
Cost of revenue $53.441 $48.956 $42.217
Gross profit $108.496 $117.033 $115.426
Operating activities
Research & development $12.062 $12.931 $12.357
Selling, general & administrative $52.55 $52.609 $53.86
Total operating expenses $107.26 $114.905 $106.974
Operating income $1.236 $2.128 $8.452
Income from continuing operations
EBIT -$11.764 $18.929 $1.334
Income tax expense -$0.613 $2.578 $31.376
Interest expense $22.206 $21.774 $23.669
Net income
Net income -$33.357 -$5.423 -$53.711
Income (for common shares) -$59.786 -$30.344 -$64.199

Cash flows

XSLX
XSLX
(in millions USD) 31 Dec 2022 30 Sep 2022 30 Jun 2022 31 Mar 2022
Net income -$8.116 -$4.138 -$18.016 -$3.087
Operating activities
Depreciation $11.387 $11.36 $11.448 $11.444
Business acquisitions & disposals
Stock-based compensation $1.028 $1.044 $1.34 $0.902
Total cash flows from operations $18.993 -$7.142 $1.834 $2.487
Investing activities
Capital expenditures -$1.413 -$0.95 -$1.076 -$0.596
Investments
Total cash flows from investing -$1.413 -$0.95 -$1.076 -$0.596
Financing activities
Dividends paid -$10.621
Sale and purchase of stock $0.154 $0.146
Net borrowings -$0.83 -$0.842 -$0.808 -$0.823
Total cash flows from financing -$0.676 -$4.174 -$3.928 -$4.846
Effect of exchange rate $1.804 -$3.633 -$4.55 $0.291
Change in cash and equivalents $18.708 -$15.899 -$7.72 -$2.664
(in millions USD) 2022 2021 2020
Net income -$33.357 -$5.423 -$53.711
Operating activities
Depreciation $45.639 $45.745 $46.97
Business acquisitions & disposals
Stock-based compensation $4.314 $3.067 $3.44
Total cash flows from operations $16.172 $52.002 $26.715
Investing activities
Capital expenditures -$4.035 -$4.023 -$2.395
Investments
Total cash flows from investing -$4.035 -$4.023 -$2.395
Financing activities
Dividends paid -$10.621 -$13.933 -$5.244
Sale and purchase of stock $0.3 $0.268 $0.316
Net borrowings -$3.303 -$12.39 -$138.415
Total cash flows from financing -$13.624 -$31.385 -$4.859
Effect of exchange rate -$6.088 -$4.694 $0.752
Change in cash and equivalents -$7.575 $11.9 $20.213

AIMT
Aimmune Therapeutics Inc
Compare

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

XSLX
XSLX
(in millions USD) 30 Jun 2020 31 Mar 2020 31 Dec 2019 30 Sep 2019
Current assets
Cash $266.559 $298.418 $79.88 $76.844
Short term investments $47.394 $59.933 $63.633 $118.626
Net receivables $0.025 $0.772
Inventory $5.646 $4.076
Total current assets $323.641 $367.82 $149.077 $202.236
Long term investments $4.127 $13.256 $14.661 $5.038
Property, plant & equipment $36.937 $38.419 $40.116 $40.617
Goodwill & intangible assets
Total noncurrent assets $41.645 $52.232 $55.292 $46.162
Total investments $51.521 $73.189 $78.294 $123.664
Total assets $365.286 $420.052 $204.369 $248.398
Current liabilities
Accounts payable $15.107 $13.952 $13.882 $11.941
Deferred revenue
Short long term debt $2.399 $2.315 $2.257 $2.163
Total current liabilities $43.001 $45.419 $47.448 $43.605
Long term debt $140.785 $138.074 $51.552 $50.935
Total noncurrent liabilities $142.427 $139.586 $52.897 $52.101
Total debt $143.184 $140.389 $53.809 $53.098
Total liabilities $185.428 $185.005 $100.345 $95.706
Stockholders' equity
Retained earnings -$880.356 -$811.112 -$724.68 -$657.782
Other stockholder equity $0.239 $0.163 $0.08 $0.14
Total stockholder equity $179.858 $235.047 $104.024 $152.692
(in millions USD) 2019 2018 2017
Current assets
Cash $79.88 $107.511 $73.487
Short term investments $63.633 $196.421 $108.943
Net receivables
Inventory
Total current assets $149.077 $312.619 $189.111
Long term investments $14.661
Property, plant & equipment $40.116 $26.328 $17.205
Goodwill & intangible assets
Total noncurrent assets $55.292 $26.936 $17.823
Total investments $78.294 $196.421 $108.943
Total assets $204.369 $339.555 $206.934
Current liabilities
Accounts payable $13.882 $8.833 $5.095
Deferred revenue
Short long term debt $2.257
Total current liabilities $47.448 $38.012 $26.599
Long term debt $51.552
Total noncurrent liabilities $52.897 $2.596 $2.53
Total debt $53.809
Total liabilities $100.345 $40.608 $29.129
Stockholders' equity
Retained earnings -$724.68 -$476.234 -$265.482
Other stockholder equity $0.08 -$0.108 -$0.108
Total stockholder equity $104.024 $298.947 $177.805

Income statement

XSLX
XSLX
(in millions USD) 30 Jun 2020 31 Mar 2020 31 Dec 2019 30 Sep 2019
Revenue
Total revenue $0.575
Cost of revenue $4.85 $0.257
Gross profit -$4.85 $0.318
Operating activities
Research & development $23.047 $36.463 $30.125 $30.558
Selling, general & administrative $38.094 $49.138 $36.861 $34.044
Total operating expenses $61.141 $85.601 $66.986 $64.602
Operating income -$65.991 -$85.283 -$66.986 -$64.602
Income from continuing operations
EBIT -$65.711 -$84.084 -$60.047 -$64.602
Income tax expense $0.321 $0.119 $0.743 -$0.104
Interest expense $3.212 $2.229 $6.108 -$0.043
Net income
Net income -$69.244 -$86.432 -$66.898 -$64.455
Income (for common shares) -$69.244 -$86.432 -$66.898 -$64.455
(in millions USD) 2019 2018 2017
Revenue
Total revenue
Cost of revenue
Gross profit
Operating activities
Research & development $123.987 $133.42 $89.325
Selling, general & administrative $125.817 $81.921 $43.949
Total operating expenses $249.804 $215.341 $133.274
Operating income -$249.804 -$215.341 -$133.274
Income from continuing operations
EBIT -$242.865 -$215.341 -$133.274
Income tax expense $0.716 $0.061 $0.056
Interest expense $4.916 -$4.65 -$2.005
Net income
Net income -$248.497 -$210.752 -$131.325
Income (for common shares) -$248.497 -$210.752 -$131.325

Cash flows

XSLX
XSLX
(in millions USD) 30 Jun 2020 31 Mar 2020 31 Dec 2019 30 Sep 2019
Net income -$69.244 -$86.432 -$66.898 -$64.455
Operating activities
Depreciation $1.44 $1.298 $1.178 $1.157
Business acquisitions & disposals
Stock-based compensation $11.814 $10.303 $8.343 $8.081
Total cash flows from operations -$55.108 -$71.812 -$52.563 -$50.85
Investing activities
Capital expenditures -$0.488 -$0.319 -$0.953 -$2.234
Investments $21.729 $5.183 $45.444 $54.336
Total cash flows from investing $21.241 $4.864 $44.491 $52.102
Financing activities
Dividends paid
Sale and purchase of stock $199.907 $11.108 $3.028
Net borrowings $85
Total cash flows from financing $2 $285.476 $11.108 $3.028
Effect of exchange rate $0.008 $0.01
Change in cash and equivalents -$31.859 $218.538 $3.036 $4.28
(in millions USD) 2019 2018 2017
Net income -$248.497 -$210.752 -$131.325
Operating activities
Depreciation $4.086 $1.598 $0.966
Business acquisitions & disposals
Stock-based compensation $32.929 $32.732 $16.719
Total cash flows from operations -$195.408 -$169.128 -$99.605
Investing activities
Capital expenditures -$8.047 -$9.42 -$6.425
Investments $119.946 -$86.59 $48.987
Total cash flows from investing $111.899 -$96.01 $42.562
Financing activities
Dividends paid
Sale and purchase of stock $20.406 $299.162 $6.52
Net borrowings $36.144
Total cash flows from financing $55.878 $299.162 $6.52
Effect of exchange rate
Change in cash and equivalents -$27.631 $34.024 -$50.523